Efpeglenatide

Overview

Efpeglenatide belongs to the incretin-mimetic class of peptides that activate the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. Unlike native GLP-1 (half-life of minutes), efpeglenatide is built on the exendin-4 backbone and conjugated to an immunoglobulin Fc domain, which resists enzymatic breakdown and extends exposure to allow weekly dosing.

The pivotal AMPLITUDE-O trial randomized 4,076 people with type 2 diabetes and a history of cardiovascular or kidney disease to weekly efpeglenatide (4 or 6 mg) or placebo. Efpeglenatide significantly reduced the risk of major adverse cardiovascular events and a composite kidney function outcome, and it did so regardless of concomitant SGLT2-inhibitor use. As an exendin-based agent, it added evidence that cardiovascular benefit is a broad GLP-1 receptor-agonist class effect rather than being limited to human-GLP-1-analog molecules.

Gastrointestinal side effects (nausea, diarrhea, vomiting) are the most common adverse events and are managed with gradual dose escalation.

Mechanism of Action

By binding the GLP-1 receptor on pancreatic beta cells, efpeglenatide amplifies insulin secretion only when glucose is elevated, limiting hypoglycemia risk. Central and gastrointestinal GLP-1 receptor signaling reduces food intake and slows gastric emptying, driving weight loss. Cardiorenal benefits observed in AMPLITUDE-O are thought to reflect a combination of glycemic, weight, blood-pressure, and possibly direct vascular and anti-inflammatory effects common to the GLP-1 receptor-agonist class.

Reconstitution Calculator